Mylan Nv Ord Shs (MYL) 39.97 $MYL
Next Support Level for Mylan (MYL) is $40.95
Comtex SmarTrend(R) - Fri Sep 02, 9:10AM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $42.03 and have already reached the first level of support at $41.44. Should the shares continue to fall, the support pivots of $40.95 and $39.87 will be of interest.
MYL: 39.97 (-1.95)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.98 (+0.08), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), BMY: 56.35 (-0.41), NVS: 79.38 (+1.11)
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Clinton offers plan to prevent 'excessive' drug price hikes
By CATHERINE LUCEY - AP - Fri Sep 02, 6:08AM CDT
DES MOINES, Iowa (AP) — Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.
MYL: 39.97 (-1.95)
Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding
PR Newswire - Thu Sep 01, 2:12PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. This is the third patent related to Copaxone® 40 mg/mL to be found unpatentable in the last week.
MYL: 39.97 (-1.95)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 1.59% Loss
Comtex SmarTrend(R) - Wed Aug 31, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.02 to a high of $42.63. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.47 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 39.97 (-1.95)
20 Democratic senators blast steep price hike for EpiPens
By MATTHEW DALY - AP - Tue Aug 30, 4:51PM CDT
WASHINGTON (AP) — In a sign of growing concern in Congress, 20 Democratic senators are demanding answers about steep price hikes for the life-saving EpiPen injector device.
MYL: 39.97 (-1.95)
Company News for August 30, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:10AM CDT
Companies in the News are: MYL,HLF,CZR,CORE
HLF: 61.35 (+0.18), MYL: 39.97 (-1.95), CZR: 6.15 (-0.08), CORE: 38.61 (+0.81)
Business Highlights
By The Associated Press - AP - Mon Aug 29, 5:07PM CDT
WASHINGTON (AP) — ___
INO: 9.08 (-0.06), MDLZ: 44.19 (+0.24), HSY: 99.30 (-0.24), MYL: 39.97 (-1.95), UAL: 51.09 (+0.20)
Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 72.54 (+0.32), MYL: 39.97 (-1.95)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 235.96 (-1.80), GNRX: 24.40 (-0.14), PRGO: 90.75 (-0.50), AXGN: 8.89 (-0.10), AKRX: 26.47 (-0.21), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), AMPH: 18.56 (-0.43), NVS: 79.38 (+1.11)
Mylan Promises $300 Generic EpiPen
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 12:04PM CDT
Pharmaceutical company Mylan NV (MYL) announced Monday that it will launch a generic version of the EpiPen at a 50% discount to the standard version of its popular allergy medication.
MYL: 39.97 (-1.95)
Watch for Shares of Mylan (MYL) to Approach Resistance at $44.56
Comtex SmarTrend(R) - Mon Aug 29, 8:34AM CDT
Mylan (NASDAQ:MYL) has opened bullishly above the pivot of $43.21 today and has reached the first level of resistance at $43.80. Analysts will be watching for a cross of the next upside pivot targets of $44.56 and $45.91.
MYL: 39.97 (-1.95)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 31.79 (-1.58), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), USNA: 138.16 (+1.81), TEVA: 51.22 (+0.32)
Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product
PR Newswire - Mon Aug 29, 5:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"
, of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths. Mylan also intends to continue to market and distribute branded EpiPen®.
MYL: 39.97 (-1.95)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.79 (-1.58), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), USNA: 138.16 (+1.81)
Is the "Internet of Things" a Fad or the Future?
Madeleine Johnson - Zacks Investment Research - Fri Aug 26, 11:11AM CDT
On today's episode of the Zacks Friday Finish Line podcast, the hosts discussed Mylan's (MYL) epipen controversy, Amazon's (AMZN) rumored new music streaming service, and whether or not the "Internet of Things" is here to stay.
AMZN: 772.44 (+1.82), MYL: 39.97 (-1.95)
Next Support Level for Mylan (MYL) is $40.95
Comtex SmarTrend(R) - Fri Sep 02, 9:10AM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $42.03 and have already reached the first level of support at $41.44. Should the shares continue to fall, the support pivots of $40.95 and $39.87 will be of interest.
MYL: 39.97 (-1.95)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.98 (+0.08), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), BMY: 56.35 (-0.41), NVS: 79.38 (+1.11)
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Clinton offers plan to prevent 'excessive' drug price hikes
By CATHERINE LUCEY - AP - Fri Sep 02, 6:08AM CDT
DES MOINES, Iowa (AP) — Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.
MYL: 39.97 (-1.95)
Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding
PR Newswire - Thu Sep 01, 2:12PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. This is the third patent related to Copaxone® 40 mg/mL to be found unpatentable in the last week.
MYL: 39.97 (-1.95)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 1.59% Loss
Comtex SmarTrend(R) - Wed Aug 31, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.02 to a high of $42.63. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.47 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 39.97 (-1.95)
20 Democratic senators blast steep price hike for EpiPens
By MATTHEW DALY - AP - Tue Aug 30, 4:51PM CDT
WASHINGTON (AP) — In a sign of growing concern in Congress, 20 Democratic senators are demanding answers about steep price hikes for the life-saving EpiPen injector device.
MYL: 39.97 (-1.95)
Company News for August 30, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:10AM CDT
Companies in the News are: MYL,HLF,CZR,CORE
HLF: 61.35 (+0.18), MYL: 39.97 (-1.95), CZR: 6.15 (-0.08), CORE: 38.61 (+0.81)
Business Highlights
By The Associated Press - AP - Mon Aug 29, 5:07PM CDT
WASHINGTON (AP) — ___
INO: 9.08 (-0.06), MDLZ: 44.19 (+0.24), HSY: 99.30 (-0.24), MYL: 39.97 (-1.95), UAL: 51.09 (+0.20)
Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 72.54 (+0.32), MYL: 39.97 (-1.95)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 235.96 (-1.80), GNRX: 24.40 (-0.14), PRGO: 90.75 (-0.50), AXGN: 8.89 (-0.10), AKRX: 26.47 (-0.21), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), AMPH: 18.56 (-0.43), NVS: 79.38 (+1.11)
Mylan Promises $300 Generic EpiPen
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 12:04PM CDT
Pharmaceutical company Mylan NV (MYL) announced Monday that it will launch a generic version of the EpiPen at a 50% discount to the standard version of its popular allergy medication.
MYL: 39.97 (-1.95)
Watch for Shares of Mylan (MYL) to Approach Resistance at $44.56
Comtex SmarTrend(R) - Mon Aug 29, 8:34AM CDT
Mylan (NASDAQ:MYL) has opened bullishly above the pivot of $43.21 today and has reached the first level of resistance at $43.80. Analysts will be watching for a cross of the next upside pivot targets of $44.56 and $45.91.
MYL: 39.97 (-1.95)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 31.79 (-1.58), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), USNA: 138.16 (+1.81), TEVA: 51.22 (+0.32)
Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product
PR Newswire - Mon Aug 29, 5:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"
, of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths. Mylan also intends to continue to market and distribute branded EpiPen®. MYL: 39.97 (-1.95)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.79 (-1.58), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), USNA: 138.16 (+1.81)
Is the "Internet of Things" a Fad or the Future?
Madeleine Johnson - Zacks Investment Research - Fri Aug 26, 11:11AM CDT
On today's episode of the Zacks Friday Finish Line podcast, the hosts discussed Mylan's (MYL) epipen controversy, Amazon's (AMZN) rumored new music streaming service, and whether or not the "Internet of Things" is here to stay.
AMZN: 772.44 (+1.82), MYL: 39.97 (-1.95)
